Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jul 24;9:2896. doi: 10.1038/s41467-018-05315-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2018

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — IFN gene therapy activates adaptive immunity. a Percentage (mean ± SEM) of OVA-specific T cells in the PB of IFN (n = 14–6) and CTRL (n = 15–8) mice. **p < 0.01, Mann Whitney performed at 9 days upon OVA-ALL injection. Each dot represents a mouse (one out of five experiments is shown). b Absolute numbers (mean±SEM) of OVA-specific T cells in the BM and spleen, 9 days upon tumor injection, in IFN (n = 23) and CTRL (n = 26) mice from 3 independent experiments. **p < 0.01, ***p < 0.001, Mann–Whitney. Each dot represents a mouse. c Splenic CD8⁺ T cells from IFN (n = 7) and CTRL (n = 8) mice 9 days upon tumor injection or from non tumor-bearing mice tested by IFNγ-ELISPOT against the EL4 target cell line transduced with NGFR-OVA or NGFR-hCD20 bidirectional LV. Concanavalin A (ConA) stimulation is used as positive control. Each dot represents a mouse. d Experimental design and percentage (mean±SEM) of OVA-ALL in the PB of IFN (n = 9), CD8-depleted IFN (n = 7) and CTRL (n = 9) mice. **p < 0.01, ****p < 0.0001, nonparametric rank-based method for longitudinal data in factorial experiments